Folate-tagged liposomes made Vitamin D3 twice as potent to breast cancer cells — lab study
pH-Sensitive Folate-Targeted Liposomal Vitamin D Reprograms EZH2/STAT3 Axis and Induces Apoptosis, ROS, and Autophagy in MCF-7 Breast Cancer Cells
Advanced Pharmaceutical Bulletin, July 1, 2026, https://doi.org/10.34172/apb.467912
Abbaspour-Rvasjani S, Shahvalizadeh R, Safavi M, Afrashteh Nour M, Talebi M, Mohammadi M, Hamishehkar H.
Summary by Claude - July, 2026
This is a laboratory (in-vitro) study in a single breast cancer cell line (MCF-7), so treat it as an early proof-of-concept about drug delivery, not as advice about taking vitamin D. Researchers packed vitamin D3 (cholecalciferol) into tiny liposomes decorated with folate — which docks onto folate receptors that breast cancer cells overproduce — and engineered them to fall apart in the acidic environment inside tumors, dumping their cargo where it's needed.
The targeting worked. Folate-tagged liposomes were taken up far more by folate-hungry MCF-7 cells, and the dose needed to kill half the cells (IC50) dropped from about 15 IU/mL for free vitamin D3, to ~11 for plain liposomes, to ~7.2 IU/mL for the folate-targeted version — roughly doubling potency. At the molecular level the targeted formulation raised VDR (the vitamin D receptor) 3.2-fold while cutting two cancer-driving proteins, EZH2 by ~60% and STAT3 by ~50%. It also boosted apoptosis (programmed cell death), reactive oxygen species, and autophagy markers, and suppressed long-term colony formation by ~90% versus untargeted liposomes. The nanoparticles were sub-100 nm, >97% loaded, stable for 60 days refrigerated, and caused negligible red-blood-cell damage.
No animals and no humans — only cells in a dish.
Results come from one cell line (MCF-7), so they may not hold for triple-negative or HER2+ breast cancer, and there's no test against healthy breast cells. The active concentrations are pharmacologic culture doses delivered directly into cells, which say nothing about oral vitamin D or blood 25(OH)D levels. The authors did not confirm that ROS or autophagy actually cause the cell death (no inhibitor/knockdown experiments), and there's no data on biodistribution, pharmacokinetics, or safety in a living body.
Related in VitaminDWiki
- Nanoemulsion, nanoliposome, and conventional Vitamin D compared
- Liposomal Vitamin D benefits, need more data
- Liposomal Vitamin D3 compared with Calcidiol(Calcifediol)
Cancer
- Vitamin D inside of a folate nanoball, Cancer cells attract folate
- Overview Breast Cancer and Vitamin D
- Breast Cancer survival improved 3.6X by 2,000 IU of Vitamin D with chemotherapy – RCT
- Breast Cancer reduces receptor and thus blocks Vitamin D to the cells – several studies
- Analysis of 280 Breast Cancer meta-analyses: having low vitamin D was highly suggestive – umbrella
- Women with Breast Cancer were 16.9 times more likely to have a poor Vitamin D Receptor
Nanoremulsion